Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Isoniazid

FDA-approved product (tablet, oral), marketed as Dow-Isoniazid, Hyzyd, Inh and 5 more.

Registered studies
50+
Lab records
268
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Isoniazid
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • Pulmonary tuberculosis
  • Silicosis
  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Hydrazides
FDA pharmacologic class
Antimycobacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AC01; WHO ATC J04AC51; FDA class Antimycobacterial

Repurposing investigation

Isoniazid is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA8.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli7.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae3.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 241 of 268 lab records
Open Isoniazid in ChEMBL Registered studies below
Show the latest 150 of 268 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Isoniazid with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV

    NCT00080119 · start 2004-02

    Registered record
    Registry ID
    NCT00080119
    Conditions
    HIV Infection; Tuberculosis; Pneumocystis Jiroveci Pneumonia
    Interventions
    Isoniazid (INH); Trimethoprim/Sulfamethoxazole (TMP/SMX); Isoniazid Placebo (PL)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2004-02
    Completion
    2009-05
    Enrolment
    1,354

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection; Tuberculosis; Pneumocystis Jiroveci Pneumonia
    InterventionIsoniazid (INH); Trimethoprim/Sulfamethoxazole (TMP/SMX); Isoniazid Placebo (PL)
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • High-Dose Isoniazid Adjuvant Therapy for Multidrug Resistant Tuberculosis

    NCT00513396 · start 2004-01

    Registered record
    Registry ID
    NCT00513396
    Conditions
    Tuberculosis, Multidrug-Resistant
    Interventions
    Isoniazid; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2004-01
    Completion
    2006-12
    Enrolment
    134

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Multidrug-Resistant
    InterventionIsoniazid; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

    NCT00042289 · start 2003-06-09

    Registered record
    Registry ID
    NCT00042289
    Conditions
    HIV Infections
    Interventions
    atazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3; elvitegravir/cobicistat; dolutegravir; tenofovir alafenamide fumarate (TAF); TAF w/cobicistat; TAF w/cobicistat or ritonavir; efavirenz; darunavir/cobicistat; lopinavir/ritonavir dosage #1; atazanavir/ritonavir/tenofovir dosage #1; rifampicin; ethambutol; isoniazid; pyrazinamide; kanamycin; amikacin; capreomycin; moxifloxacin; levoflaxacin; ofloxacin; ethionamide/prothionamide; terizidone/cycloserine; para-aminosalicylic acid (PAS); high dose INH; bedaquiline; clofazamine; delamanid; linezolid; pretomanid; ethinyl estradiol; etonogestrel implant; nevirapine; amprenavir; abacavir; lopinavir/ritonavir dosage #2; indinavir/ritonavir dosage #1; fosamprenavir/ritonavir; lopinavir/ritonavir dosage #3; atazanavir/ritonavir dosage #1; didanosine delayed release (Videx® EC); emtricitabine; tenofovir; nelfinavir dosage #1; tipranavir/ritonavir; lopinavir/ritonavir dosage #4; ralteg
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2003-06-09
    Completion
    2020-09-30
    Enrolment
    1,578

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionatazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3 +45 more
    PhaseNot recorded
    Registry statusCompleted

  • Preventive Therapy for Tuberculosis in HIV Infected Persons

    NCT00351702 · start 2001-02

    Registered record
    Registry ID
    NCT00351702
    Conditions
    Human Immunodeficiency Virus; Tuberculosis
    Interventions
    Isoniazid with Ethambutol
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-02
    Completion
    2011-06
    Enrolment
    683

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus; Tuberculosis
    InterventionIsoniazid with Ethambutol
    PhasePhase 3
    Registry statusCompleted

  • Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis

    NCT00000950

    Registered record
    Registry ID
    NCT00000950
    Conditions
    HIV Infections; Tuberculosis
    Interventions
    Ethambutol hydrochloride; Isoniazid; Pyrazinamide; Pyridoxine hydrochloride; Rifampin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Tuberculosis
    InterventionEthambutol hydrochloride; Isoniazid; Pyrazinamide; Pyridoxine hydrochloride +1 more
    PhaseNot applicable
    Registry statusCompleted